Safety evaluation
ADVERSE EVENT
After 16 weeks of treatment, the incidence of AEs was 46.2% (48/104) and 44.2% (23/52) in the PEG-Loxe and metformin groups, respectively (Summary of safety.AE, adverse event; SAE, serious adverse event; SOC, system organ class; PT, preferred term.At week 16, the change in ALT was -6.88 U/L (95% CI: -7.54, -6.22) with PEG-Loxe and -2.33 U/L (95% CI: -3.17, -1.48) with metformin (